Brind.

InflaRx, a company based in Germany, maintains offices and subsidiaries in Jena, Munich, and Ann Arbor.

4 reports, 2 independent Updated Aug 21
Gone quiet Reached 2 outlets in its first 24 hours
Reports
4
Developments
1
Repetition
75%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

InflaRx, a company based in Germany, maintains offices and subsidiaries in Jena, Munich, and Ann Arbor.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireInflaRx Announces Participation in September Investor Conferences JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammator
  • GlobeNewswireInflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of
  • ZacksInflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates InflaRx N.V. (IFRX) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to a loss
  • GlobeNewswireInflaRx to Report Second Quarter 2025 Results on August 7, 2025 JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory